logo
Graphjet visited by Japanese trading company

Graphjet visited by Japanese trading company

New York, United States, July 23, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology ('Graphjet' or 'the Company') was honoured to welcome a delegation from a Japanese trading company with international presence for an official visit on JULY 23, 2025 to discuss on the provision of sustainable graphite materials to their customers.
This visit highlights the Japanese trading company's strong interest in Graphjet's proprietary technology, which utilize palm kernel shells as a renewable feedstock to produce high purity synthetic graphite. This patented process significantly reduce carbon emissions compared to traditional graphite production methods, aligning with global efforts toward decarbonization and green manufacturing.
With over 75 years of history, this renowned Japanese enterprise is one of the major integrated trading houses in Asia, actively engaged in diverse sectors including aerospace components, advanced machinery and automation systems, and chemical products, it serves industry leaders across multiple sector for customers like Toshiba and Hitachi. With annual revenue of around ¥‎30 billion, the firm maintains operations in North America, Europe, and Southeast Asia.
During the visit, the delegation toured Graphjet's R&D production facilities, gaining valuable insights into the company's manufacturing process and quality assurance system.
'This engagement marks a meaningful step forward in strengthening mutual understanding and laying the groundwork for future collaboration in the field of sustainable graphite and next generation technology.' said Chris Lai the CEO of Graphjet.
Graphjet Technology remains committed to advancing green innovation and building strong partnership with global industry leaders to drive sustainable progress in the graphite and graphene sector.
About Graphjet Technology Sdn. Bhd.
Graphjet Technology Sdn. Bhd. (Nasdaq: GTI) was founded in 2019 in Malaysia as an innovative graphene and graphite producer. Graphjet Technology has the world's first patented technology to recycle palm kernel shells generated in the production of palm seed oil to produce single layer graphene and artificial graphite. Graphjet's sustainable production methods utilizing palm kernel shells, a waste agricultural product that is common in Malaysia, will set a new shift in graphite and graphene supply chain of the world. For more information, please visit https://www.graphjettech.com/.
Cautionary Statement Regarding Forward-Looking Statements
The information in this press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'aim,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result' and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Graphjet competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Graphjet will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) Graphjet is beginning the commercialization of its technology and it may not have an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Graphjet's industry and market size; (v) financial condition and performance of Graphjet, including the anticipated benefits, the implied enterprise value, the financial condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Graphjet; (vi) Graphjet's ability to develop and manufacture its graphene and graphite products; and (vii) those factors discussed in our filings with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the 'Risk Factors' section of the documents to be filed by Graphjet from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Graphjet may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Graphjet does not give any assurance that Graphjet will achieve its expectations.
Graphjet Technology Contacts
Investors
[email protected]
Media
[email protected]
###
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regeneron Pharmaceuticals Earnings Preview: What to Expect
Regeneron Pharmaceuticals Earnings Preview: What to Expect

Yahoo

time25 minutes ago

  • Yahoo

Regeneron Pharmaceuticals Earnings Preview: What to Expect

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $61.8 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The biotechnology company is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Friday, Aug. 1. Ahead of the event, analysts expect REGN to report a profit of $6.23 per share on a diluted basis, down 38.3% from $10.10 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect REGN to report EPS of $28.27, down 26.8% from $38.62 in fiscal 2024. However, its EPS is expected to rise 9.3% year over year to $30.90 in fiscal 2026. REGN stock has significantly underperformed the S&P 500 Index's ($SPX) 17.3% gains over the past 52 weeks, with shares down 46.8% during this period. Similarly, it considerably underperformed the Health Care Select Sector SPDR Fund's (XLV) 9.4% dip over the same time frame. REGN is facing challenges due to declining sales of its key drug Eylea, amid increased competition from Roche Holding AG's (RHHBY) Vabysmo and potential biosimilars. The company's partnership with Sanofi (SNY) has also seen setbacks, including mixed results from late-stage studies on itepekimab. These factors have negatively impacted REGN's stock performance, and the company has a tough road ahead in diversifying its revenue streams and offsetting the decline in Eylea sales. On Apr. 29, REGN shares closed down by 6.9% after reporting its Q1 results. Its adjusted EPS of $8.22 fell short of Wall Street's expectations of $8.43. The company's revenue was $3 billion, falling short of Wall Street forecasts of $3.3 billion. Analysts' consensus opinion on REGN stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 25 analysts covering the stock, 17 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' six give a 'Hold,' and one recommends a 'Moderate Sell.' REGN's average analyst price target is $737.71, indicating a potential upside of 30.7% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio

Amalgamated Financial: Q2 Earnings Snapshot
Amalgamated Financial: Q2 Earnings Snapshot

Yahoo

time37 minutes ago

  • Yahoo

Amalgamated Financial: Q2 Earnings Snapshot

NEW YORK (AP) — NEW YORK (AP) — Amalgamated Financial Corp. (AMAL) on Thursday reported second-quarter earnings of $26 million. On a per-share basis, the New York-based company said it had profit of 84 cents. Earnings, adjusted for non-recurring costs, were 88 cents per share. The bank posted revenue of $112.1 million in the period. Its adjusted revenue was $80.9 million. Amalgamated Financial shares have decreased roughly 9% since the beginning of the year. The stock has declined 4.5% in the last 12 months. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on AMAL at Sign in to access your portfolio

AI tech detects hidden heart disease doctors often miss
AI tech detects hidden heart disease doctors often miss

Fox News

time2 hours ago

  • Fox News

AI tech detects hidden heart disease doctors often miss

You might think heart disease comes with warning signs. But some of the deadliest types, like structural heart disease (SHD), creep in silently. No chest pain. No shortness of breath. Nothing until it's too late. Now, a new artificial intelligence tool called EchoNext is changing the game. It can flag hidden heart problems that even trained cardiologists miss just by analyzing a standard ECG. That's right. A routine, five-minute heart test you've probably already had could now unlock life-saving information if AI is watching. Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my SHD refers to defects in the heart's walls, valves or chambers. Some are present at birth. Others develop slowly over time. Either way, they often go unnoticed until something major happens, like a heart attack or stroke. That's why experts sometimes call SHD the "hidden" heart disease. Here's the problem. Even the ECGs doctors routinely use to spot heart issues often can't detect SHD on their own. And that's where EchoNext comes in. EchoNext was created by researchers at Columbia University and NewYork-Presbyterian. The tool was trained on over 1.2 million ECG and echocardiogram pairs from more than 230,000 patients. Its job? Figure out when a patient's ECG suggests a deeper look is needed, specifically, an echocardiogram, the ultrasound that gives a detailed view of heart structure. "EchoNext basically uses the cheaper test to figure out who needs the more expensive one," explained Dr. Pierre Elias, who led the study. And the results? Stunning. In tests, EchoNext correctly flagged 77% of structural heart disease cases from ECGs. Cardiologists? Just 64%. Even more impressive, when tested on nearly 85,000 people, EchoNext identified over 7,500 at high risk for undiagnosed SHD. A year later, researchers found that 73% of those who followed up with echocardiograms were indeed diagnosed with SHD, a rate far above average. These groundbreaking results were published in Nature, one of the world's most respected scientific journals. That's not just a better test. That's a potential lifesaver. Millions walk around every day with SHD and have no idea. They skip heart screenings because nothing feels wrong. Even when they do get an ECG, subtle warning signs can slip by unnoticed. EchoNext doesn't miss them. And it doesn't get tired or distracted. This isn't about replacing doctors. Iit's about giving them a powerful new tool to catch what humans alone can't. You don't need to wait for symptoms to take your heart health seriously. If you've ever had an ECG, or you're getting one soon, AI could now help spot hidden risks your doctor might miss. Tools like EchoNext make it easier to catch heart problems early, even if you feel fine. This means fewer surprises, fewer missed diagnoses and a better shot at treatment before it's too late. It's not about replacing doctors. It's about giving them, and you, a better shot at catching problems early. Ask your doctor if AI tools are being used to review your heart tests. You deserve every advantage. Right now, EchoNext is being used in research settings, but tools like it are quickly moving toward wider use in hospitals and clinics. AI is no longer the future of medicine. It's happening now. EchoNext proves that machine learning can radically improve how we detect silent killers like SHD. If a simple ECG plus AI could save thousands of lives, what are we waiting for? Would you trust a machine to catch what your cardiologist might overlook? Let us know by writing us at Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my Copyright 2025 All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store